TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00957723

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon® CR Total Knee System
Description: The purpose is to evaluate the Triathlon® CR Total Knee System.
Study: NCT00146224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa RB
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa DT
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
Study: NCT00626795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD1414 2% cream
Description: BID 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD1414 2% cream
Description: TID 7 days
Study: NCT01448824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Administered orally
Study: NCT01370837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of Candida albicans antigen.
Description: Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of Candida albicans antigen.
Description: Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of Candida albicans antigen.
Description: Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement.
Description: Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement.
Description: Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement.
Description: Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
Study: NCT00787930

Intervention type: DRUG
Intervention: Valproic Acid
Description: Tablets, 250mg-3000mg

Intervention type: DRUG
Intervention: Valproic Acid
Description: Tablets, 250mg-3000mg
Study: NCT01696344

Intervention type: PROCEDURE
Intervention: PVAI

Intervention type: PROCEDURE
Intervention: PVAI + ablation of extraPV triggers
Description: PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
Study: NCT02666456

Intervention type: OTHER
Intervention: QST, Questionnaires
Description: Assessment of sensory phenotype by QST and questionnaires

Intervention type: OTHER
Intervention: QST, Questionnaires
Description: Assessment of sensory phenotype by QST and questionnaires
Study: NCT04492709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
Study: NCT00958464

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
Study: NCT03618628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Off Loading Orthosis (CFO)
Description: A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
Study: NCT04150731

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 16α-18F-fluor-17β-estradiol
Description: 16α-18F-fluor-17β-estradiol PET/CT scan
Study: NCT00626795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactroban® (mupirocin) 2% cream
Description: BID 7 days
Study: NCT02993783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion
Study: NCT01984294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669
Description: GS-9669 tablet(s) administered orally once daily
Study: NCT02630420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab and savolitinib
Description: Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
Study: NCT01741532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution
Description: Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A deferiprone matching placebo oral solution will be given twice daily for 18 months.
Study: NCT01984294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669
Description: GS-9669 tablet(s) administered orally once daily
Study: NCT05663827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
Study: NCT00740688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic Apex Contact
Description: A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Logan Basic apex contact
Description: light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
Study: NCT04104893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
Study: NCT00669591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
Study: NCT02531919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Given PO
Study: NCT01064986

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin, Lipopolysaccharide, LPS
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin, Lipopolysaccharide, LPS /Epinephrine
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline vehicle (placebo)
Study: NCT01618617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose Multistrain probiotic, 100 billion cfu/day
Description: 100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
Study: NCT01064986

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone
Study: NCT01618617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose Multistrain probiotic, 15 billion cfu/day
Description: 15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
Study: NCT02417285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
Study: NCT01453946

Intervention type: DRUG
Group type: OTHER
Intervention: Entocort
Description: Entocort capsules, taken orally, 6 mg daily.
Study: NCT02469597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
Study: NCT01110486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348 and carboplatin
Description: An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348 and docetaxel
Description: ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
Study: NCT01178372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics(VSL#3)
Description: will receive VSL#3 (110 billion CFU)three times a day
Study: NCT01110486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
Study: NCT04022590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-clothes
Description: The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy consultation
Description: Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy consultation
Description: Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
Study: NCT04420065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preferential left ventricular pacing
Description: Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
Study: NCT02807194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar disc herniation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar disc herniation
Study: NCT00639808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: 60 ml IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
Study: NCT02299544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlueWind Medical system
Description: The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
Study: NCT01873196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive extra oil

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receives behavior changed messages on CSB package
Study: NCT01911884

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: evaluate quality of life of surgical and non surgical vaginal aplasia
Description: protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
Study: NCT04652349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1910
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1903
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1909
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1911
Description: Take it once daily for 8 weeks orally.
Study: NCT05839002

Intervention type: PROCEDURE
Intervention: nCRT
Description: ESCC patients that recieved surgery and nCRT.

Intervention type: PROCEDURE
Intervention: nCRT
Description: ESCC patients that recieved surgery and nCRT.
Study: NCT01197495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid gel
Description: Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid gel
Description: Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
Study: NCT03113799

Intervention type: DEVICE
Group type: OTHER
Intervention: Smart External Drain - SED
Description: Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
Study: NCT03419377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care and sexological counseling
Description: 6-8 sexological consultants in a period of six months
Study: NCT05082350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black garlic
Description: Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black garlic
Description: Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
Study: NCT03430505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel
Description: Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
Study: NCT03745183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Senna alata leaf decoction
Description: Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko.
Study: NCT04393688

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter
Description: Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter
Description: Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.
Study: NCT02921711

Intervention type: DEVICE
Intervention: LVIS®
Description: Low-profile Visualized Intraluminal Support device
Study: NCT02380612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell Treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Graft
Study: NCT02713607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Given doxycycline to acne subjects
Study: NCT04545177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICO Myriad and Tissue Preservation System (TPS)
Description: Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
Study: NCT02335047

Intervention type: OTHER
Group type: OTHER
Intervention: Impaired passivity test
Description: Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
Study: NCT01118104

Intervention type: OTHER
Group type: OTHER
Intervention: Vocational pulmonary rehabilitation
Description: Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
Study: NCT02125903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
Study: NCT00896363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK163090 1 mg
Description: Developed for the treatment of Major Depressive Disorder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK163090 Placebo
Description: Developed for the treatment of Major Depressive Disorder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK163090 3 mg
Description: Developed for the treatment of Major Depressive Disorder